Evidence map›Paper›PMID 40051843›Full record

ArticleHeliyon2025

Inhibitory effects of saffron compounds on multiple sclerosis: Molecular docking and dynamic, enhancing properties with gold nanoparticles and evaluating antioxidant, antibacterial, cytotoxicity.

Shaghayegh Mohammadi, Hamed Farjam, Sharieh Hosseini, Kambiz Larijani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shaghayegh MohammadiDepartment of Chemistry, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Hamed FarjamDepartment of Chemistry, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Sharieh HosseiniDepartment of Chemistry, Faculty of Pharmaceutical Chemistry, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Kambiz LarijaniDepartment of Chemistry, Science and Research Branch, Islamic Azad University, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The unique properties of nanoparticles, such as their small size and the ability to cross the blood-brain barrier, make them well-suited for targeted drug delivery to the central nervous system. Ongoing research is dedicated to developing innovative nanoparticle-based therapies for a neurological disorder; multiple sclerosis (MS). The study confirmed green synthesis as the optimal method for producing environmentally friendly compounds. The nanoparticles were characterized by Fourier transform infrared spectroscopy (FT-IR), X-ray powder diffraction (XRD), and transmission electron microscopy (TEM). To evaluate the antioxidant properties, we employed the 2,2-diphenyl-1-picrylhydrazyl (DPPH) method, while conducting a comprehensive examination of antibacterial activity against both Gram-negative (

Indexed as

AntibacterialGold nanoparticleMolecular dockingMTT assayMultiple sclerosisSaffron

Identifiers

PMID40051843
PMCPMC11883381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.